Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
K
348150
vs
K
KOSPI 200
Over the past 12 months, KoBioLabs Inc has underperformed KOSPI 200, delivering a return of -46% compared to KOSPI 200's +119% growth.
Stocks Performance
348150 vs KOSPI 200
Performance Gap
348150 vs KOSPI 200
Performance By Year
348150 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
KoBioLabs Inc
Glance View
KoBioLabs is a South Korean biotechnology company built around microbiome research. It develops products that use beneficial bacteria or related ingredients for health, skin care, and nutrition. In simple terms, it turns its research into items people can buy and into ingredients that other companies can use in their own products. The company makes money in two main ways: selling finished consumer products under its own brands and supplying microbiome-related ingredients or materials to business customers. Its customers include everyday shoppers looking for health or beauty products, as well as other companies in food, cosmetics, and health care that need specialty ingredients. What makes KoBioLabs different is its place in the value chain. It does not just package generic products; it focuses on developing and commercializing microbiome science, which sits between research labs and consumer goods. That gives it a business model tied to product development, brand sales, and ingredient partnerships rather than traditional manufacturing alone.